e8vk

Exhibit 99.1

(ANS LOGO) FOR IMMEDIATE RELEASE


Agency Contact:		Company Contact:
Neil Berkman Associates		Chris Chavez, President & CEO
(310) 277-5162		(972) 309-8000
info@BerkmanAssociates.com		www.ANS-medical.com

Advanced Neuromodulation Systems
Announces Stock Repurchase Plan

DALLAS, TEXAS, June 1, 2004 — Advanced Neuromodulation Systems, Inc. (ANS) (NASDAQ:ANSI) today announced that its Board of Directors has approved the repurchase of up to 1,000,000 shares of the Company’s common stock. Repurchases will be made from time to time in open market purchases or privately negotiated transactions, subject to price and availability, and financed out of working capital. The company’s common stock is listed on the NASDAQ National Market System.

Christopher G. Chavez, President and Chief Executive Officer of ANS, said that the Board believes that the company’s stock has traded at very attractive investment levels recently, that the company’s stock is currently undervalued, and that using available working capital to purchase up to 1,000,000 shares would represent the best use of corporate funds in the current environment.

ANS currently has about 20 million issued and outstanding shares. At March 31, 2004, ANS had total assets of $200 million, of which $93 million is in cash and cash equivalents. ANS has no debt.

About Advanced Neuromodulation Systems

Advanced Neuromodulation Systems designs, develops, manufactures and markets implantable systems used to manage chronic intractable pain and other disorders of the central nervous system. Forbes magazine recently recognized ANS as one of America’s 200 Best Small Companies and Fortune magazine recently recognized ANS as one of Fortune’s Top 100 Fastest-Growing Small Companies in the United States. Frost & Sullivan, an international strategic market research firm, also recently presented ANS with its Product Innovation Award, recognizing ANS as the technology innovation leader in the neurostimulation market and ANS’ Genesis® Implantable Pulse Generator system as the most advanced fully implantable spinal cord stimulator on the market. Additional information is available at www.ans-medical.com.

“Safe harbor” statement under the Private Securities Litigation Reform Act of 1995:

Statements contained in this document that are not based on historical facts are “forward-looking statements.” Terms such as “plan,” “should,” “would,” “anticipate,” “believe,” “intend,” “estimate,” “expect,” “predict,” “scheduled,” “new market,” “potential market applications” and similar expressions are intended to identify forward-looking statements. Such statements are by nature subject to uncertainties and risks, including but not limited to: the launch of new competitive products by Medtronic, Advanced Bionics or others, as well as other market factors, could impede growth in or reduce sales of our IPG and RF systems, which could adversely affect our revenues and profitability; continued market acceptance of the Genesis® IPG and GenesisXP^TM IPG; competition from Medtronic, Advanced Bionics and future competitors; continued market acceptance of our Renew® system; patient or physician selection of less invasive or less expensive alternatives; adverse changes in coverage or reimbursement amounts by Medicare, Medicaid, private insurers, managed care organizations or workers’ comp programs; intellectual property protection and potential infringement issues; the cost, uncertainty and other risks inherent in our intellectual property litigation against Advanced Bionics; obtaining necessary government approvals for our rechargeable IPGs and other new products or applications and maintaining compliance with FDA product and manufacturing requirements; product liability; reliance on single suppliers for certain components; completion of research and development projects in an efficient and timely manner; the satisfactory completion of clinical trials and/or market tests prior to the introduction of new products; successful integration of acquired businesses, products and technologies; the cost, uncertainty and other risks inherent in patent and intellectual property litigation; international trade risks; and other risks detailed from time to time in the Company’s SEC filings. Consequently, if such management assumptions prove to be incorrect or such risks or uncertainties materialize, anticipated results could differ materially from those forecast in forward-looking statements. Such forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release.


Texas	0-10521	75-1646002

(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)


	Item 9. “Regulation FD Disclosure.”
SIGNATURES
INDEX TO EXHIBITS
Press Release


Dated:	June 2, 2004

		ADVANCED NEUROMODULATION SYSTEMS, INC.

		By:	/s/ F. Robert Merrill III

			Name:	F. Robert Merrill III
			Title:	Executive Vice President, Finance,
				Chief Financial Officer and Treasurer


Exhibit
Number		Description
99.1		Press Release dated June 1, 2004 (This press release shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act)

Table of Contents

Table of Contents

Table of Contents

Table of Contents